ANI Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. 是一家多元化生物製藥公司，通過開發、製造和營銷品牌和仿製處方藥產品（包括針對未滿足醫療需求的疾病）爲有需要的患者提供服務。該公司專注於通過其主要資產 Purified Cortrophin Gel 擴大其罕見病業務以及通過增強研發能力的仿製藥業務，實現可持續增長。該公司擁有三家制藥廠，其中兩家位於明尼蘇達州的 Baudette，一家位於新澤西州的 East Windsor，這些工廠共同能夠生產口服固體劑量產品以及半固體、液體和外用藥、管制物質和強效產品。該公司擁有約 118 種產品的商業組合，具有多種適應症和強大的產品線組合。

ANI Pharmaceuticals Inc簡介



公司代碼ANIP

公司名稱ANI Pharmaceuticals Inc

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

員工數量897

證券類型Ordinary Share

年結日May 04

公司地址210 Main Street West

城市BAUDETTE

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編56623

電話12186343500

網址https://www.anipharmaceuticals.com/

公司代碼ANIP

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

ANI Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-12.17%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-6.53%

Mr. Patrick D. Walsh

Independent Chairman of the Board

70.05K

-11.39%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

60.19K

-4.31%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

40.04K

-11.05%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

36.52K

-34.62%

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

26.96K

+19.17%

Mr. Matthew J. (Matt) Leonard

Independent Director

6.86K

-57.96%

名稱

名稱/職務

職務

持股

持股變動

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-12.17%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-6.53%

Mr. Patrick D. Walsh

Independent Chairman of the Board

70.05K

-11.39%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

60.19K

-4.31%

收入明細

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Sales of generic pharmaceutical products

90.30M

0.00%

Sales of rare disease pharmaceutical products

81.65M

0.00%

Sales of Cortrophin Gel

81.65M

0.00%

Sales of branded pharmaceutical products

17.11M

0.00%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Sales of generic pharmaceutical products

90.30M

0.00%

Sales of rare disease pharmaceutical products

81.65M

0.00%

Sales of Cortrophin Gel

81.65M

0.00%

Sales of branded pharmaceutical products

17.11M

0.00%

股東統計

更新時間: 8月17日週日

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.64%

The Vanguard Group, Inc.

5.71%

Meridian Venture Partners

4.55%

Millennium Management LLC

4.50%

Global Alpha Capital Management Ltd.

3.87%

其他

70.72%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

10.64%

The Vanguard Group, Inc.

5.71%

Meridian Venture Partners

4.55%

Millennium Management LLC

4.50%

Global Alpha Capital Management Ltd.

3.87%

其他

70.72%

股東類型

持股股東

佔比

Investment Advisor

44.67%

Investment Advisor/Hedge Fund

21.80%

Hedge Fund

17.80%

Individual Investor

7.52%

Private Equity

4.55%

Research Firm

3.65%

Corporation

2.86%

Bank and Trust

1.67%

Pension Fund

1.63%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

501

21.40M

95.98%

-2.10M

2025Q2

505

24.45M

112.92%

-1.14M

2025Q1

511

24.19M

111.77%

-1.42M

2024Q4

489

23.75M

109.53%

-1.38M

2024Q3

473

23.30M

110.79%

+2.44M

2024Q2

446

19.77M

94.29%

-402.06K

2024Q1

424

18.72M

89.20%

-877.00K

2023Q4

409

18.10M

88.69%

-881.29K

2023Q3

396

18.38M

91.57%

-127.77K

2023Q2

370

17.73M

90.91%

+852.82K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.37M

10.64%

-68.37K

-2.80%

Jun 30, 2025

The Vanguard Group, Inc.

1.27M

5.71%

+95.32K

+8.09%

Jun 30, 2025

Meridian Venture Partners

1.01M

4.55%

-150.00K

-12.88%

Aug 21, 2025

Millennium Management LLC

1.00M

4.5%

-112.78K

-10.10%

Jun 30, 2025

Global Alpha Capital Management Ltd.

862.09K

3.87%

+126.50K

+17.20%

Jun 30, 2025

State Street Investment Management (US)

716.12K

3.21%

+1.55K

+0.22%

Jun 30, 2025

Deep Track Capital LP

700.00K

3.14%

--

Jun 30, 2025

Esjay L.L.C,

632.62K

2.84%

-200.00K

-24.02%

Mar 14, 2025

Citadel Advisors LLC

569.63K

2.56%

-153.70K

-21.25%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

553.89K

2.48%

-77.67K

-12.30%

Jun 30, 2025

持股ETF



更新時間: 11月2日週日

機構名稱

佔比

Invesco Pharmaceuticals ETF

2.7%

SPDR S&P Pharmaceuticals ETF

2.26%

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.03%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.69%

Innovator IBD 50 Fund ETF

1.3%

Invesco Dorsey Wright Healthcare Momentum ETF

1.07%

Janus Henderson Small/Mid Cap Growth Alpha ETF

1.04%

Invesco S&P SmallCap Health Care ETF

1.01%

Innovator IBD Breakout Opportunities ETF

0.9%

First Trust Small Cap Growth AlphaDEX Fund

0.7%

Invesco Pharmaceuticals ETF

佔比2.7%

SPDR S&P Pharmaceuticals ETF

佔比2.26%

Pacer US Small Cap Cash Cows Growth Leaders ETF

佔比2.03%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.69%

Innovator IBD 50 Fund ETF

佔比1.3%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.07%

Janus Henderson Small/Mid Cap Growth Alpha ETF

佔比1.04%

Invesco S&P SmallCap Health Care ETF

佔比1.01%

Innovator IBD Breakout Opportunities ETF

佔比0.9%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.7%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據